Patents by Inventor Kevin J. Tracey

Kevin J. Tracey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7238715
    Abstract: A method of treating a patient suffering from pancreatitis comprising treating said patient with a therapeutically effective amount of a cholinergic agonist selective for an ?7 nicotinic receptor in an amount sufficient to decrease the amount of the proinflammatory cytokine that is released from a macrophage wherein said condition is acute pancreatitis. The compounds of the present invention include a quaternary analog of cocaine; (1-aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid 1-(2-fluorophenyl)-ethyl ester; a compound of formula (I), a compound of formula (II), a compound of formula (III), a compound of formula (IV), and an oligonucleotide or mimetic capable of attenuating the symptoms of acute pancreatitis wherein the oligonucleotide or mimetic consists essentially of a sequence greater than 5 nucleotides long that is complementary to an mRNA of an ?7 cholinergic receptor.
    Type: Grant
    Filed: September 30, 2004
    Date of Patent: July 3, 2007
    Assignee: The Feinstein Institute for Medical Research
    Inventors: Kevin J. Tracey, Hong Wang
  • Patent number: 7220723
    Abstract: The invention features a method of treating an inflammatory condition in an individual, comprising administering an agent that inhibits the interaction between a Toll-like receptor 2 (TLR2) and a high mobility group B (HMGB) polypeptide to the individual. The invention also features methods for identifying agents that inhibit the interaction between TLR2 and HMGB.
    Type: Grant
    Filed: June 6, 2003
    Date of Patent: May 22, 2007
    Assignee: The Feinstein Institute for Medical Research
    Inventors: Kevin J. Tracey, Huan Yang
  • Patent number: 7192917
    Abstract: There is disclosed a pharmaceutical composition and method for treating sepsis, including, septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk or exhibit sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.
    Type: Grant
    Filed: November 21, 2003
    Date of Patent: March 20, 2007
    Assignee: The Feinstein Institute for Medical Research
    Inventors: Kevin J. Tracey, Haichao Wang
  • Patent number: 7186555
    Abstract: The present invention provides methods and pharmaceutical compositions of the human glycoprotein fetuin, or ?2-HS glycoprotein, or fragments thereof to mitigate tissue damage associated with ischemia, particularly in stroke or in myocardial infarction.
    Type: Grant
    Filed: April 13, 2000
    Date of Patent: March 6, 2007
    Assignee: The Feinstein Institute for Medical Research
    Inventors: Kevin J. Tracey, Haichao Wang
  • Patent number: 7151082
    Abstract: There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk or exhibit sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.
    Type: Grant
    Filed: November 20, 2002
    Date of Patent: December 19, 2006
    Assignee: The Feinstein Institute for Medical Research
    Inventors: Kevin J. Tracey, Haichao Wang
  • Patent number: 7097838
    Abstract: There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk or exhibit sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.
    Type: Grant
    Filed: July 31, 2002
    Date of Patent: August 29, 2006
    Assignee: The Feinstein Institute for Medical Research
    Inventors: Kevin J. Tracey, Haichao Wang
  • Patent number: 7060504
    Abstract: There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk or exhibit sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.
    Type: Grant
    Filed: September 11, 2002
    Date of Patent: June 13, 2006
    Assignee: North Shore-Long Island Jewish Research Institute
    Inventors: Kevin J. Tracey, Haichao Wang
  • Patent number: 6943190
    Abstract: This invention is directed to a method of using a therapeutic composition comprising a compound of an alpha-ketoalkanoic acid (pyruvate) and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions. The compound is an alpha-ketoalkanoic acid, a physiologically acceptable salt of an alpha-ketoalkanoic acid, an ester of an alpha-ketoalkanoic acid, or an amide of an alpha-ketoalkanoic acid. A component for inducing and stabilizing the enol resonance form of the ester at physiological pH values is also disclosed. The cytokine-mediated inflammatory conditions are mediated by, for example, an “early” (Tumor Necrosis Factor (TNF), interleukin-1? (IL-1?)) or “late” (high mobility group B-1 (HMGB-1)) mediator of inflammation.
    Type: Grant
    Filed: September 15, 2003
    Date of Patent: September 13, 2005
    Assignees: University of Pittsburgh-of the Commonwealth System of Higher Education, North Shore-Long Island Jewish Research Institute
    Inventors: Mitchell P. Fink, Luis Ulloa, Kevin J. Tracey, Russell L. Delude
  • Patent number: 6838471
    Abstract: A method of inhibiting the release of a proinflammatory cytokine in a cell is disclosed. The method comprises treating the cell with a cholinergic agonist. The method is useful in patients at risk for, or suffering from, a condition mediated by an inflammatory cytokine cascade, for example endotoxic shock. The cholinergic agonist treatment can be effected by stimulation of an efferent vagus nerve fiber, or the entire vagus nerve.
    Type: Grant
    Filed: May 28, 2003
    Date of Patent: January 4, 2005
    Assignee: North Shore-Long Island Jewish Research Institute
    Inventor: Kevin J. Tracey
  • Publication number: 20040204355
    Abstract: Methods of inhibiting release of a proinflammatory cytokine from a macrophage are provided. The methods comprise treating the macrophage with a cholinergic agonist in an amount sufficient to decrease the amount of the proinflammatory cytokine that is released from the macrophage, wherein the cholinergic agonist is selective for an &agr;7 nicotinic receptor. Methods for inhibiting an inflammatory cytokine cascade in a patient are also provided. The methods comprise treating the patient with a cholinergic agonist in an amount sufficient to inhibit the inflammatory cytokine cascade, wherein the cholinergic agonist is selective for an &agr;7 nicotinic receptor. Methods for determining whether a compound is a cholinergic agonist reactive with an &agr;7 nicotinic receptor are also provided. The methods comprise determining whether the compound inhibits release of a proinflammatory cytokine from a mammalian cell.
    Type: Application
    Filed: December 5, 2003
    Publication date: October 14, 2004
    Applicant: North Shore-Long Island Jewish Research Institute
    Inventors: Kevin J. Tracey, Hong Wang
  • Publication number: 20040171695
    Abstract: There is disclosed a method for treating diseases and disorders involving T cell activation and HIV-infection using the p38 mitogen activated protein kinase (MAPK) signaling pathway as a target for intervention. There is further disclosed a use for guanylhydrazone-substituted compounds to treat diseases and disorders related to T cell activation and HIV-infection.
    Type: Application
    Filed: July 16, 2003
    Publication date: September 2, 2004
    Inventors: Kevin J. Tracey, Pamela Cohen, Michael Bukrinsky, Helena Schmidtmayerova
  • Publication number: 20040120953
    Abstract: There is disclosed a pharmaceutical composition and method for treating sepsis, including, septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk or exhibit sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.
    Type: Application
    Filed: November 21, 2003
    Publication date: June 24, 2004
    Applicant: North Shore-Long Island Jewish Research Institute
    Inventors: Kevin J. Tracey, Haichao Wang
  • Publication number: 20040110833
    Abstract: This invention is directed to a method of using a therapeutic composition comprising a compound of an alpha-ketoalkanoic acid (pyruvate) and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions. The compound is an alpha-ketoalkanoic acid, a physiologically acceptable salt of an alpha-ketoalkanoic acid, an ester of an alpha-ketoalkanoic acid, or an amide of an alpha-ketoalkanoic acid. A component for inducing and stabilizing the enol resonance form of the ester at physiological pH values is also disclosed. The cytokine-mediated inflammatory conditions are mediated by, for example, an “early” (Tumor Necrosis Factor (TNF), interleukin-1&bgr; (IL-1&bgr;)) or “late” (high mobility group B-1 (HMGB-1)) mediator of inflammation.
    Type: Application
    Filed: September 15, 2003
    Publication date: June 10, 2004
    Applicants: University of Pittsburgh of the Commonwealth System of Higher Education, North Shore-Long Island Jewish Research Institute
    Inventors: Mitchell P. Fink, Luis Ulloa, Kevin J. Tracey
  • Publication number: 20040053841
    Abstract: The invention features a method of treating an inflammatory condition in an individual, comprising administering an agent inhibits the interaction between a Toll-like receptor 2 (TLR2) and a high mobility group B (HMGB) polypeptide to the individual. The invention also features methods for identifying agents that inhibit the interaction between TLR2 and HMGB.
    Type: Application
    Filed: June 6, 2003
    Publication date: March 18, 2004
    Applicant: North Shore-Long Island Jewish Research Institute
    Inventors: Kevin J. Tracey, Huan Yang
  • Publication number: 20040048795
    Abstract: Methods for inhibiting pro-inflammatory cytokine release or inflammation in a vertebrate are provided. The methods comprise activating a brain muscarinic receptor of the vertebrate, or directly stimulating a vagus nerve pathway in the brain of the vertebrate. Also provided are methods for conditioning a vertebrate to inhibit the release of a pro-inflammatory cytokine or reduce inflammation in the vertebrate upon experiencing a sensory stimulus. The methods comprise (a) activating a muscarinic brain receptor or directly stimulating the vagus nerve pathway in the brain of the vertebrate and providing the sensory stimulus to the vertebrate within a time period sufficient to create an association between the stimulus and the activation of the brain muscarinic receptor; and (b) repeating step (a) at sufficient time intervals and duration to reinforce the association sufficiently for the inflammation to be reduced by the sensory stimulus alone.
    Type: Application
    Filed: February 26, 2003
    Publication date: March 11, 2004
    Applicant: North Shore-Long Island Jewish Research Institute
    Inventors: Svetlana M. Ivanova, Kevin J. Tracey
  • Publication number: 20040038857
    Abstract: A method of inhibiting the release of a proinflammatory cytokine in a cell is disclosed. The method comprises treating the cell with a cholinergic agonist. The method is useful in patients at risk for, or suffering from, a condition mediated by an inflammatory cytokine cascade, for example endotoxic shock. The cholinergic agonist treatment can be effected by stimulation of an efferent vagus nerve fiber, or the entire vagus nerve.
    Type: Application
    Filed: May 28, 2003
    Publication date: February 26, 2004
    Applicant: North Shore-Long Island Jewish Research Institute
    Inventor: Kevin J. Tracey
  • Publication number: 20040005316
    Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise a vertebrate HMG A box, and an antibody preparation that specifically binds to a vertebrate HMG B box. The methods comprise treating a cell or a patient with sufficient amounts of the composition to inhibit the release of the proinflammatory cytokine, or to inhibit the inflammatory cytokine cascade.
    Type: Application
    Filed: June 6, 2003
    Publication date: January 8, 2004
    Applicant: North Shore-Long Island Jewish Research Institute
    Inventors: Kevin J. Tracey, Huan Yang
  • Patent number: 6673777
    Abstract: There is disclosed a method for treating diseases and disorders involving T cell activation and HIV-infection, using the p38 mitogen activated protein kinase (MAPK) signaling pathway as a target for intervention. There is further disclosed a use for guanylhydrazone-substituted compounds to treat diseases and disorders related to T cell activation and HIV-infection.
    Type: Grant
    Filed: November 2, 2000
    Date of Patent: January 6, 2004
    Assignee: Cytokine PharmaSciences, Inc.
    Inventors: Kevin J. Tracey, Pamela Cohen, Michael Bukrinsky, Helena Schmidtmayerova
  • Patent number: 6610713
    Abstract: A method of inhibiting the release of a proinflammatory cytokine in a cell is disclosed. The method comprises treating the cell with a cholinergic agonist. The method is useful in patients at risk for, or suffering from, a condition mediated by an inflammatory cytokine cascade, for example endotoxic shock. The cholinergic agonist treatment can be effected by stimulation of an efferent vagus nerve fiber, or the entire vagus nerve.
    Type: Grant
    Filed: May 15, 2001
    Date of Patent: August 26, 2003
    Assignee: North Shore - Long Island Jewish Research Institute
    Inventor: Kevin J. Tracey
  • Publication number: 20030143194
    Abstract: There is disclosed a pharmaceutical composition and method for treating sepsis, including, septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk or exhibit sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.
    Type: Application
    Filed: November 20, 2002
    Publication date: July 31, 2003
    Applicant: North Shore-Long Island Jewish Research Institute
    Inventors: Kevin J. Tracey, Haichao Wang